WO2014023867A3 - Liposomas vacíos como adyuvante de diferentes principios activos, administrados independientemente y en su forma galénica convencional - Google Patents

Liposomas vacíos como adyuvante de diferentes principios activos, administrados independientemente y en su forma galénica convencional Download PDF

Info

Publication number
WO2014023867A3
WO2014023867A3 PCT/ES2013/070535 ES2013070535W WO2014023867A3 WO 2014023867 A3 WO2014023867 A3 WO 2014023867A3 ES 2013070535 W ES2013070535 W ES 2013070535W WO 2014023867 A3 WO2014023867 A3 WO 2014023867A3
Authority
WO
WIPO (PCT)
Prior art keywords
indepently
active agents
liposomes administered
encapsulation
composition
Prior art date
Application number
PCT/ES2013/070535
Other languages
English (en)
French (fr)
Other versions
WO2014023867A2 (es
Inventor
Pedro González Enseñat
Original Assignee
Enoc Solutions, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enoc Solutions, S.L. filed Critical Enoc Solutions, S.L.
Publication of WO2014023867A2 publication Critical patent/WO2014023867A2/es
Publication of WO2014023867A3 publication Critical patent/WO2014023867A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La encapsulación de sustancias activas ha permitido mejoras en la administración de diferentes principios activos. Sin embargo, la encapsulación no está exenta de problemas. En la presente invención, se describe el uso de una composición que comprende liposomas en fase acuosa como adyuvante caracterizado porque dicha composición se combina de manera independiente con el principio activo.
PCT/ES2013/070535 2012-08-09 2013-07-19 Liposomas vacíos como adyuvante de diferentes principios activos, administrados independientemente y en su forma galénica convencional WO2014023867A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP201231287 2012-08-09
ES201231287A ES2442450B1 (es) 2012-08-09 2012-08-09 Liposomas vacíos como adyuvante de diferentes principios activos, administrados independientemente y en su forma galénica convencional

Publications (2)

Publication Number Publication Date
WO2014023867A2 WO2014023867A2 (es) 2014-02-13
WO2014023867A3 true WO2014023867A3 (es) 2014-04-03

Family

ID=49551608

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2013/070535 WO2014023867A2 (es) 2012-08-09 2013-07-19 Liposomas vacíos como adyuvante de diferentes principios activos, administrados independientemente y en su forma galénica convencional

Country Status (2)

Country Link
ES (1) ES2442450B1 (es)
WO (1) WO2014023867A2 (es)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0361894A2 (en) * 1988-09-28 1990-04-04 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Loading and controlled release of amphiphatic molecules to and from liposomes
US20030003144A1 (en) * 2001-05-01 2003-01-02 Keller Brian C. Sustained release formulations for nifedipine, dextromethorphan, and danazol
US20080044464A1 (en) * 2001-10-03 2008-02-21 Paul Tardi Liposome loading with metal ions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9000207A (es) * 1990-01-29 1991-08-16 Duphar Int Res
ES2196978B1 (es) * 2001-10-26 2005-03-16 Universitat Autonoma De Barcelona Composicion farmaceutica.
EP1750673B1 (en) * 2004-05-17 2009-12-02 Tekmira Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
EP3153159A1 (en) * 2004-07-09 2017-04-12 Robert Sabin Compositions comprising a copper compound for treatment of mammalian diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0361894A2 (en) * 1988-09-28 1990-04-04 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Loading and controlled release of amphiphatic molecules to and from liposomes
US20030003144A1 (en) * 2001-05-01 2003-01-02 Keller Brian C. Sustained release formulations for nifedipine, dextromethorphan, and danazol
US20080044464A1 (en) * 2001-10-03 2008-02-21 Paul Tardi Liposome loading with metal ions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Adjuvant", 12 October 2013 (2013-10-12), pages 1 - 3, XP002718158, Retrieved from the Internet <URL:http://en.wikipedia.org/wiki/Adjuvant> [retrieved on 20131217] *
KUCHERYANU ET AL: "Effect of liposomes containing L-DOPA on mice behaviour in experimental Parkinsonian syndrome", PHARMACOLOGICAL RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 31, 1 January 1995 (1995-01-01), pages 106, XP022358806, ISSN: 1043-6618, DOI: 10.1016/1043-6618(95)86682-5 *
LUDEWIG<A> B ET AL: "In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity", VACCINE, ELSEVIER LTD, GB, vol. 19, no. 1, 15 August 2000 (2000-08-15), pages 23 - 32, XP004228807, ISSN: 0264-410X, DOI: 10.1016/S0264-410X(00)00163-8 *
XIANG YU ET AL: "Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against the Parkinson's disease in the MPTP-induced mice model", JOURNAL OF DRUG TARGETING, vol. 20, no. 1, January 2012 (2012-01-01), pages 67 - 75, XP009175246 *

Also Published As

Publication number Publication date
ES2442450A2 (es) 2014-02-11
ES2442450B1 (es) 2014-12-12
ES2442450R1 (es) 2014-03-03
WO2014023867A2 (es) 2014-02-13

Similar Documents

Publication Publication Date Title
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
RS54873B1 (sr) Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
PH12015500850A1 (en) Stable preservative-free mydriatic and anti-inflammatory solutions for injection
PH12015500900A1 (en) A stabilized pemetrexed formulation
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
WO2011139252A3 (en) Efervescent formulations comprising cefdinir
ZA201404068B (en) The use of silver(i) complexes as active pharmaceutical ingredients (api&#39;s) iincluding anticancer agents
WO2012104874A3 (en) Aqueous concentrated formulation of linezolid
UA105260C2 (ru) Фармацевтическая композиция для приготовления инфузионных растворов антимикробных препаратов, способ ее получения (варианты)
WO2014023867A3 (es) Liposomas vacíos como adyuvante de diferentes principios activos, administrados independientemente y en su forma galénica convencional
AU2014269144A8 (en) Bioactive compounds
RU2011145777A (ru) Лекарственное средство, обладающее ранозаживляющей, противовоспалительной активностью
TH132573B (th) ธูป
TH119303B (th) หลอดยาดม
MY184940A (en) Lignosus rhinocerus (tiger-milk mushroom) as anti-inflammatory agent
TH130577B (th) เก้าอี้
TH130803B (th) ที่นั่ง
TH130802B (th) ที่นั่ง
TH130804B (th) ที่นั่ง

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13786680

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13786680

Country of ref document: EP

Kind code of ref document: A2